Maternal and Neonatal Circulating Markers of Metabolic and Cardiovascular Risk in the Metformin in Gestational Diabetes (MiG) Trial
Helen L. Barrett(The University of Queensland), Janet Rowan(Auckland City Hospital), William M. Hague(The University of Adelaide), Marloes Dekker Nitert(The University of Queensland), Leonie Callaway(Royal Brisbane and Women's Hospital), David McIntyre(Mater Health Services), Candice M. Houda(The University of Adelaide), Suzette Coat(The University of Adelaide), Miles J. De Blasio(Discovery Institute), Julie A. Owens(The University of Adelaide), Kathryn L. Gatford(The University of Adelaide)
Cited by 51
Related Papers
Fetal nutrition and cardiovascular disease in adult life
|The Lancet|1993|2.8k
Metformin versus Insulin for the Treatment of Gestational Diabetes
|New England Journal of Medicine|2008|1.3k
Metformin in Gestational Diabetes: The Offspring Follow-Up (MiG TOFU)
|Diabetes Care|2011|385
Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7–9 years of age
|BMJ Open Diabetes Research & Care|2018|295